Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026

Understand how pharmaceutical and biotechnology companies acquire products, technologies, business assets and royalty interests using intelligence from 891 real-world transactions.

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive intelligence on 891 asset purchase deals across the global life sciences industry.

Asset acquisitions provide companies with an alternative to acquiring an entire business, enabling buyers to secure specific products, technologies, intellectual property, business assets or royalty interests that complement their strategic and portfolio objectives.

For sellers, asset transactions can provide a route to monetize individual programs, technologies or non-core assets while retaining the wider business.

The report examines how these transactions are being used across the pharmaceutical and biotechnology sectors, which companies are most active, what types of assets are being acquired and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report helps users understand what is being acquired, who is buying and selling assets, how transactions are structured, how consideration is being allocated and how comparable agreements have been negotiated in practice.

It provides a practical intelligence and benchmarking resource for business development, corporate development, licensing, portfolio strategy, legal, transaction and competitive intelligence teams evaluating asset acquisition or divestment opportunities.

Understand the asset purchase deal landscape

The report analyzes asset purchase dealmaking from 2019 to 2026, including:

• Trends in asset purchase activity by year
• Phase of development at the time of transaction
• Industry sector
• Therapy area
• Technology type
• Most active asset purchase dealmakers
• Leading transactions by disclosed value
• Strategic reasons for undertaking asset purchase transactions
• How asset acquisition activity is evolving

The analysis covers transactions involving:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• This enables users to understand how different types of life science assets are being acquired and where transaction activity is concentrated.
• Understand how asset purchase agreements are structured
• Asset purchase transactions require precise definition of what is being transferred, which rights and obligations accompany the assets and what responsibilities remain with the buyer and seller.

The report provides intelligence to help users examine areas including:

• Assets and rights being transferred
• Intellectual property ownership and assignment
• Product and technology rights
• Royalty and economic interests
• Development and commercialization obligations
• Technology and know-how transfer
• Manufacturing and supply arrangements
• Assumed and retained liabilities
• Transition arrangements
• Representations and warranties
• Closing conditions
• Ongoing obligations between buyer and seller
• Financial consideration where disclosed
• Termination and other transaction provisions
• These real-world examples provide useful reference points when evaluating, structuring or negotiating asset acquisition and divestment transactions.
• Benchmark asset purchase financials
• The report provides access to disclosed financial information associated with individual asset purchase transactions.

Depending on the transaction, this can include:

• Upfront or closing consideration
• Deferred payments
• Development milestones
• Regulatory milestones
• Commercial milestones
• Royalty arrangements
• Contingent consideration
• Other financial commitments where disclosed
• Leading asset purchase transactions are also ranked by disclosed deal value, enabling users to identify significant precedent deals and investigate their underlying structures.
• This intelligence provides useful context when considering the potential structure and economics of comparable asset transactions.
• Identify active buyers and sellers
• The report profiles the Top 25 most active asset purchase dealmakers, providing insight into companies repeatedly acquiring or divesting pharmaceutical and biotechnology assets.

Transaction histories can help users identify:

• Companies actively acquiring products and technologies
• Organizations divesting non-core assets
• Potential buyers for assets being prepared for sale
• Competitors strengthening particular portfolios
• Companies entering new therapeutic or technology areas
• Relevant precedent transactions
• This makes the report particularly useful for corporate development, portfolio strategy, business development and competitive intelligence.
• Learn from real-world asset purchase contracts
• Where publicly available, the report provides access to underlying asset purchase contract documents.

These agreements can reveal considerably more detail than transaction announcements alone, enabling users to examine how companies have documented provisions relating to:

• Assets and intellectual property transferred
• Purchase consideration
• Milestone and royalty obligations
• Representations and warranties
• Assumed and excluded liabilities
• Development and commercialization obligations
• Technology transfer
• Transition arrangements
• Closing conditions
• Termination and continuing obligations
• For teams evaluating or preparing an asset transaction, access to real agreement language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive asset purchase deal directory
• The report includes a comprehensive directory of 891 asset purchase deals, enabling users to identify transactions relevant to their own assets, technologies and strategic objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Corporate Development and M&A teams
• Identify precedent asset acquisitions, active buyers and sellers, and relevant transaction structures.
• Business Development and Licensing teams
• Evaluate asset purchase as an alternative to licensing and identify companies acquiring or divesting relevant products and technologies.
• Portfolio Strategy teams
• Understand how companies are acquiring strategic assets and monetizing or divesting non-core programs.
• Companies Preparing Assets for Sale
• Identify potential acquirers and investigate comparable transactions involving similar products, technologies or development stages.
• Legal and Transaction teams
• Review real-world agreement structures and publicly available contract language to support due diligence, drafting and negotiation.
• Competitive Intelligence teams
• Track how competitors are using asset acquisitions and divestments to reshape pipelines, portfolios and strategic focus.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying asset purchase intelligence to the customer's own business, products, technologies or transaction objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective buyers or sellers, competitor acquisition activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.